Spinogenix Announces World Health Organization Approval of "Codabakalner" as International Nonproprietary Name for SPG601

Spinogenix announced Codabakalner is entering Phase 2b/3 development for Fragile X Syndrome. The move from earlier-stage research to a pivotal mid/late-stage program is a positive clinical milestone, though no efficacy/safety results or financial terms were provided in the excerpt.

Analysis

Spinogenix announced Codabakalner is entering Phase 2b/3 development for Fragile X Syndrome. The move from earlier-stage research to a pivotal mid/late-stage program is a positive clinical milestone, though no efficacy/safety results or financial terms were provided in the excerpt.